Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile

SAN DIEGO, December 11, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that data presented in a poster session at the American Society of Hematology (ASH) 59th Meeting and Annual Exhibition demonstrate clinical activity, including one partial response, for the company’s lead product […]

eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects

SAN DIEGO, November 10, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster presentation of preclinical data for its lead product candidate, eFT508, that defines its immunological mechanism of action and activation of anti-tumor immune response. In vitro and in […]

eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer

SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has initiated dosing in a Phase 2 clinical study of eFT508 in combination with avelumab* in microsatellite stable colorectal cancer (MSS CRC). The trial (NCT03258398) is being conducted […]

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

SAN DIEGO, July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing. Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments. All existing investors […]

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

SAN DIEGO, June 20, 2017 – eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).

eFFECTOR Therapeutics Presents Phase 1 Data on eFT508, Its Lead Product Candidate, at ASCO 2017

SAN DIEGO, June 5, 2017 – Today, eFFECTOR Therapeutics presented Phase 1 clinical trial data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. In a poster entitled, “A Phase 1 Dose Escalation Study of eFT508, an Inhibitor of Mitogen-Activated Protein Kinase-Interacting Serine/Threonine Kinase-1 (MNK-1) and MNK-2 in Patients with Advanced Solid Tumors,” […]

eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017

SAN DIEGO, April 3, 2017 – eFFECTOR Therapeutics yesterday presented positive preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. In a poster entitled “eFT508, a potent and highly selective inhibitor of MNK1/2, regulates immune checkpoint and cytokine expression promoting anti-tumor immunity,” eFFECTOR scientists presented data demonstrating that eFT508, […]

eFFECTOR Therapeutics’ Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma

SAN DIEGO, March 9, 2017 – eFFECTOR Therapeutics today announced that its lead product candidate, eFT508, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. eFT508 is a potent, highly selective inhibitor of MNK1 and […]

eFFECTOR Therapeutics Appoints Jeremy Barton, M.D., as Chief Medical Officer

SAN DIEGO, September 15, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that Jeremy Barton, M.D., has joined eFFECTOR as chief medical officer. Dr. Barton brings a long and successful track record in oncology drug development to eFFECTOR, having held leadership positions at large […]

eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting

SAN DIEGO, March 18, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced the preclinical profile of lead product candidate eFT508 will be presented at a special drug development track session titled “New Drugs on the Horizon 2” at the Annual Meeting of the American […]